top of page

Company Profile

Nanoglia, Inc., is a global new company that specialized in research

and development of innovative medicines using Nanotechnology

for brain diseases, Osteoathritis, and neuropathic pain.

History

2022.08    과학기술일자리진흥원 충남대학교 "대학기술경영촉진(TMC)사업" 선정

2022.08    대전테크노파크 "기술거래촉진네트워크사업" 선정

2020.11    Subsidiary of Chungnam National University Technology Holding Company

2020.05    Fund raising from 5 shareholders and 3 directors selected

2019.04    Established Nanoglia, Inc.

Patent

2022.08 Transfer

 

No. 10-2113090 : p38 또는 이를 코딩하는 유전자의 발현을 억제하는 제제가 함유된 나노입자를 포함하는 신경병증성통증 예방 또는 치료용 조성

Composition for preventing or treating neuropathic pain comprising nanoparticle containing an agent for inhibiting expression of p38 or a gene encoding the same

 Address. 102 (M1), 266, Munhwa-ro, Jung-gu, Daejeon, 35015, Republic of Korea

Tel. 82+ 42-580-8210

© 2023 by ITG. Proudly created with Wix.com

bottom of page